今夜，又见证历史！

Core Viewpoint - Eli Lilly has become the first healthcare company to reach a market capitalization of $1 trillion, driven by investor enthusiasm for its weight loss drugs [11][12]. Market Performance - On November 21, U.S. stock markets showed mixed results, with the Dow Jones rising over 220 points, while the Nasdaq index experienced volatility [1]. - The S&P 500 index has seen a decline of over 2% for the week, with the Dow down nearly 3% and the Nasdaq retreating about 3% [7]. Federal Reserve Signals - Federal Reserve officials, including Williams, have indicated a more dovish stance, raising expectations for a potential interest rate cut in December, with the probability now exceeding 70% [4][6]. - Investors are hopeful that a more accommodative monetary policy could stimulate the economy and support high valuations in the tech sector [6]. Eli Lilly's Market Position - Eli Lilly's stock price rose by 1.7%, pushing its market capitalization to approximately $1 trillion, making it the largest pharmaceutical company by market value [12]. - The company's GLP-1 class drugs, used for obesity and diabetes treatment, have garnered significant market interest, with projections estimating the market size could reach $95 billion by 2030 [12][14]. - Eli Lilly's market share in the GLP-1 segment has approached 58%, showcasing its rapid growth in the obesity treatment market [14]. Challenges Faced by Eli Lilly - Despite its successes, Eli Lilly has faced challenges, including high tariff threats and political risks surrounding prescription drug pricing [14]. - The company experienced a setback when CVS Health removed its weight loss drug Zepbound from its preferred list, favoring a competitor's product [14].